Not available
Quote | vTv Therapeutics Inc. (NASDAQ:VTVT)
Last: | $18.28 |
---|---|
Change Percent: | -0.31% |
Open: | $17.64 |
Close: | $18.28 |
High: | $19.15 |
Low: | $17.0562 |
Volume: | 45,028 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | vTv Therapeutics Inc. (NASDAQ:VTVT)
2024-06-26 16:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D Cadisegliatin has been dosed in over ...
Message Board Posts | vTv Therapeutics Inc. (NASDAQ:VTVT)
Subject | By | Source | When |
---|---|---|---|
2 week long runs in past on news | 81vette | investorshub | 03/06/2023 5:28:28 PM |
Zero borrow and not optionable,low float target $4,insider | 81vette | investorshub | 03/06/2023 3:06:16 PM |
Zero borrow and not optionable,low float target $4,insider | 81vette | investorshub | 03/06/2023 3:06:15 PM |
https://finviz.com/quote.ashx?t=VTVT&ty=c&ta=1&p=d | TheFinalCD | investorshub | 02/27/2023 1:03:17 PM |
whytestocks: $VTVT News Article - vTv Therapeutics Announces Paul Sekhri as new President and Chief | whytestocks | investorshangout | 07/27/2022 12:11:01 PM |
News, Short Squeeze, Breakout and More Instantly...
vTv Therapeutics Inc. Company Name:
VTVT Stock Symbol:
NASDAQ Market:
vTv Therapeutics Inc. Website:
2024-06-26 16:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D Cadisegliatin has been dosed in over ...
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING PR Newswire WESTON, Fla. , May 28, 2024 /PRNewswire/ -- Cantex Pharmaceuticals , Inc., a clinical stage pharmaceutical company focused on developi...